Abstract
Eighty-three patients with transient ischemic attack (TIA) were randomly divided into study group (n=42) and control group (n=41) from July, 2011 to Mar, 2015. Patients in both groups were given aspirin 100 mg/d; in addition, patients in study group received intravenous infusion of argatroban 10 mg, q12h, for 7 days and those in control group received subcutaneous injection of low molecular weight heparin (LMWH) 2 050 AXa IU, b. i.d for 7 days. The cases with cure, significantly effectiveness and effectiveness in study group and control group were 10, 14, 16 and 6, 12 16, respectively. Compared with the control group, argatroban shows superiority in treatment of TIA with higher safety and lower side effect. Key words: Ischemic attack, transient; Anticoagulants
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
